ABBOTT LABORATORIES Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments
ABBOTT LABORATORIES (ABT) reported Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments of $92.00 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-02.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments · last filed 2024-05-02
- ABBOTT LABORATORIES gain (loss) on foreign currency derivative instruments not designated as hedging instruments for the quarter ending 2024-03-31 was $92.00M.
- ABBOTT LABORATORIES gain (loss) on foreign currency derivative instruments not designated as hedging instruments for the quarter ending 2023-03-31 was -$103.00M.
- ABBOTT LABORATORIES gain (loss) on foreign currency derivative instruments not designated as hedging instruments for the quarter ending 2022-03-31 was -$51.00M.
- ABBOTT LABORATORIES gain (loss) on foreign currency derivative instruments not designated as hedging instruments for fiscal 2023 was -$44.00M, a 162.86% decline from fiscal 2022.
- ABBOTT LABORATORIES gain (loss) on foreign currency derivative instruments not designated as hedging instruments for fiscal 2022 was $70.00M, a 268.42% increase from fiscal 2021.
- ABBOTT LABORATORIES gain (loss) on foreign currency derivative instruments not designated as hedging instruments for fiscal 2021 was $19.00M.
- ABBOTT LABORATORIES gain (loss) on foreign currency derivative instruments not designated as hedging instruments for fiscal 2020 was -$171.00M.
| Period end | Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 3 month | Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 12 month |
|---|---|---|
| 2024-03-31 | $92.00M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | -$44.00M 10-K · filed 2024-02-16 | |
| 2023-03-31 | -$103.00M 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $70.00M 10-K · filed 2024-02-16 | |
| 2022-03-31 | -$51.00M 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $19.00M 10-K · filed 2024-02-16 | |
| 2020-12-31 | -$171.00M 10-K · filed 2023-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |